| | Study | City, country | | Delay for early DMSA scan | Threshold used for PCT (ng/mL) | Results |
| | Benador, 1998 [22] | Geneva, Switz. | 80 | Within 5 days | >0.6 | Se: 70%; Sp: 83% |
| | Gervaix, 2001 [21] | Geneva, Switz. | 57 | Within 5 days | ≥0.5 | Se: 74% (56–87); Sp: 85% (62–97) |
| | Smolkin, 2002 [24] | Afula, Israel | 64 | Within 7 days | ≥0.5 | Se: 94%; Sp: 90%; PPV: 86%; NPV: 98% |
| |
Pecile, 2004 [16] | Udine, Italy | 100 | Within 5 days | ≥0.5 | Se: 91%; Sp: 70%; PPV: 78%; NPV: 87% | | ≥0.8 | Se: 83%; Sp: 94%; PPV: 94%; NPV: 83% | | ≥1.0 | Se: 81%; Sp: 94%; PPV: 94%; NPV: 81% |
| | Gurgoze, 2005 [18] | Firat, Turkey | 76 | Within 7 days | >0.5 | Se: 58%; Sp: 76% |
| | Bigot, 2005 [19] | Lille, France | 42 | Within 3 days | ≥0.5 | Se: 100%; Sp: 87 %; PPV: 86 %; NPV: 100% |
| | Tuerlinckx, 2005 [20] | Yvoir, Belgium | 63 | Within 3 days | ≥0.5 | Se: 68%; Sp: 23% |
| |
Güven, 2006 [26] | Antalya, Turkey | 33 | Within 3 days | ≥1.7 | Se: 46%; Sp: 77% | | ≥0.5 | Se: 65%; Sp: 38%; PPV: 62%; NPV: 42% | | ≥1.0 | Se: 77%; Sp: 45%; PPV: 48%; NPV: 75% | | ≥2.0 | Se: 100%; Sp: 43%; PPV: 24%; NPV: 100% |
| |
Karavanaki, 2007 [27] | Athens, Greece | 58 | Within 7 days | ≥0.5 | Se: 94%; Sp: 76%; PPV: 68%; NPV: 96% | | ≥0.8 | Se: 94%; Sp: 88%; PPV: 80%; NPV: 96% | | ≥1.0 | Se: 94%; Sp: 100%; PPV: 100%; NPV: 97% |
| | Belhadj-Tahar, 2008 [23] | Toulouse, France | 183 | Day 4 | | PCT were significantly higher in patients with early scintigrahic alteration (7.85 versus 2.36 ng/mL) |
| | Kotoula, 2009 [31] | Thrase, Greece | 57 | Within 7 days | ≥0.85 | Se: 89%; Sp: 97%, PPV: 56%; NPV: 91% |
| | Bressan, 2009 [17] | Padova, Italy | 72 | Within 7 days | | Results focused on scars |
| |
Nikfar, 2009 [25] | Ahvaz, Iran | 100 | Within 7 days | ≥0.5 | Se: 77% (65–87); Sp: 89% (75–97); | | PPV: 92% (81–98); NPV: 71% (56–83) |
|
|
